Home Cart Sign in  
Chemical Structure| 1458630-17-5 Chemical Structure| 1458630-17-5

Structure of CHR-6494 TFA
CAS No.: 1458630-17-5

Chemical Structure| 1458630-17-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CHR-6494 TFA is a haspin kinase inhibitor.

Synonyms: CHR-6494 TFA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CHR-6494 TFA

CAS No. :1458630-17-5
Formula : C18H17F3N6O2
M.W : 406.36
SMILES Code : O=C(C(F)(F)F)O.CCCNC1=NN2C(C=C1)=NC=C2C3=CC=C4C(C=NN4)=C3
Synonyms :
CHR-6494 TFA
MDL No. :MFCD24849399
InChI Key :ILWYDZNXJQESDI-UHFFFAOYSA-N
Pubchem ID :91691123

Safety of CHR-6494 TFA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U2OS cells 600 nM 28 h To study the effect of CHR-6494 on the cell cycle of U2OS cells, results showed that CHR-6494 delayed the entry of cells into mitosis. J Cell Physiol. 2020 May;235(5):4508-4519
HeLa cells 300 nM 15 h To study the effect of CHR-6494 on the cell cycle of HeLa cells, results showed that CHR-6494 delayed the entry of cells into mitosis. J Cell Physiol. 2020 May;235(5):4508-4519
MDA-MB-231 cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M arrest and subsequent apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
HCT-116 cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M arrest and subsequent apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
HeLa cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M arrest and subsequent apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
MCF7 cells 200 nmol/L 96 h To evaluate the effect of CHR-6494 on MLN8237 sensitivity, results showed that CHR-6494 significantly enhanced the killing effect of MLN8237. Cancer Commun (Lond). 2021 Feb;41(2):121-139
SKBR3 cells 200 nmol/L 72 h To evaluate the effect of CHR-6494 on MLN8237 sensitivity, results showed that CHR-6494 significantly enhanced the killing effect of MLN8237. Cancer Commun (Lond). 2021 Feb;41(2):121-139
MDA-MB-231 cells 200 nmol/L 72 h To evaluate the effect of CHR-6494 on MLN8237 sensitivity, results showed that CHR-6494 significantly enhanced the killing effect of MLN8237. Cancer Commun (Lond). 2021 Feb;41(2):121-139

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT-116 human colorectal cancer xenograft model Intraperitoneal injection 50 mg/kg Once daily for 5 consecutive days, total 15 days CHR-6494 showed antitumor activity without observed toxicity Oncogene. 2012 Mar 15;31(11):1408-18
Nude mice MDA-MB-231 xenograft model Oral and intraperitoneal injection 20 mg/kg Once daily for 15 consecutive days To evaluate the antitumor effect of CHR-6494 in combination with MLN8237, results showed that the combination treatment significantly inhibited tumor growth. Cancer Commun (Lond). 2021 Feb;41(2):121-139

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.61mL

4.92mL

2.46mL

References

 

Historical Records

Categories